Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK

by Kinjel Shah

FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

by Zacks Equity Research

Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.

Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal

by Zacks Equity Research

Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

by Zacks Equity Research

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

by Zacks Equity Research

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.

Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.

Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down

by Zacks Equity Research

Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.

Merck (MRK) Gets Priority Tag for Antiviral Drug Prevymis sNDA

by Zacks Equity Research

The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.

Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE Cibinqo for Adolescents, Updates From NVO, RHHBY

by Kinjel Shah

FDA approves Pfizer's (PFE) Cibinqo for adolescent patients. Roche (RHHBY) announces new positive data from phase III studies on Vabysmo for vision loss associated with retinal vein occlusion.

Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.

Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up

by Zacks Equity Research

Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO

by Kinjel Shah

AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.

Will Biogen (BIIB) Beat Estimates This Earnings Season?

by Zacks Equity Research

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and neuroscience franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.

Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.

Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal

by Zacks Equity Research

Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.

Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?

by Zacks Equity Research

Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.

J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat

by Zacks Equity Research

J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

by Zacks Equity Research

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication

by Zacks Equity Research

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

by Zacks Equity Research

Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.